PDT Partners LLC Takes $1.03 Million Position in CeriBell, Inc. $CBLL

PDT Partners LLC acquired a new stake in shares of CeriBell, Inc. (NASDAQ:CBLL) during the second quarter, Holdings Channel reports. The firm acquired 52,725 shares of the company’s stock, valued at approximately $1,026,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CBLL. Strs Ohio bought a new position in CeriBell during the 1st quarter valued at $27,000. Caitong International Asset Management Co. Ltd raised its stake in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of CeriBell in the third quarter valued at $33,000. CWM LLC lifted its holdings in shares of CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares in the last quarter.

CeriBell News Roundup

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG Research raised its price target for CBLL to $30 from $28 and reiterated a Buy rating. Canaccord Genuity also increased its target to $26, while the overall analyst consensus remains “Moderate Buy.”
• Positive Sentiment: Several institutional investors recently increased or initiated positions in CeriBell, including Caitong International Asset Management, CWM LLC, Tower Research Capital and Legal & General, although the dollar values of these holdings remain modest.
• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares worth about $307,000. The executives retained substantial positions, and the filings identified tax withholding after equity vesting as the reason for the sales. CeriBell insider transaction report
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from August 10. The zero-day days-to-cover figure offers little useful information and may reflect anomalous reporting.
• Negative Sentiment: CeriBell’s latest quarterly results were mixed: revenue of $28.10 million exceeded expectations, but adjusted earnings of negative $0.51 per share missed the consensus estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss of approximately $1.96 per share.
• Negative Sentiment: The coordinated selling by multiple senior executives may create a modest overhang, particularly with the shares near their 52-week high. The impact is tempered by the sales’ stated tax-related purpose and the executives’ continued ownership.

Analysts Set New Price Targets

Several brokerages have commented on CBLL. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Canaccord Genuity Group raised their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Barclays raised shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Finally, BTIG Research increased their target price on shares of CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.40.

Insider Activity at CeriBell

In other CeriBell news, CRO Joseph S. Manni sold 1,361 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $24.02, for a total value of $32,691.22. Following the completion of the transaction, the executive directly owned 55,956 shares in the company, valued at $1,344,063.12. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Raymond Woo sold 1,979 shares of CeriBell stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58. Following the completion of the transaction, the chief technology officer directly owned 194,729 shares in the company, valued at approximately $4,677,390.58. This trade represents a 1.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 382,067 shares of company stock valued at $8,025,866. Corporate insiders own 17.70% of the company’s stock.

CeriBell Stock Performance

Shares of NASDAQ CBLL opened at $23.45 on Thursday. The stock’s fifty day simple moving average is $19.89 and its 200 day simple moving average is $19.30. The stock has a market capitalization of $900.01 million, a price-to-earnings ratio of -13.32 and a beta of 0.81. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. As a group, sell-side analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.